Older age used to be a prohibitive factor for receiving a bone marrow/stem cell transplant, but this is changing. This presentation reviews the evidence that some older patients can be good candidates for transplant as well as CAR T-cell therapy and how to assess their risks.

Stem cell transplants in older patients have, historically, had lower success rates than those in younger patients. This presentation describes several new promising strategies to improve transplant outcomes and survival rates in older patients. Many thanks to Pharmacyclics, an AbbVie Company, and Janssen Biotech, Inc., Jazz Pharmaceuticals and Omeros Corporation, whose support, in part helped make this workshop possible.

Los cánceres de sangre que se presentan con mayor frecuencia en adultos mayores se pueden tratar con un trasplante de médula ósea o células madre o con terapia de células CAR T. Sin embargo, a menudo no se les ofrecen estos tratamientos. Conozca por qué esto debería cambiar.

Descubra cómo se pueden optimizar los resultados para los adultos mayores que están considerando un trasplante de células madre o una terapia de células CAR T con programas que aborden sus necesidades médicas y psicosociales únicas.